Navigation Links
Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report
Date:12/22/2013

DUBLIN, Dec. 22, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/wj54rz/ophthalmic#summary) has announced the addition of the "Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Ophthalmic pharmaceutical drugs is a uniquely competitive market kept perennially vibrant by refining technological changes in drug formulations and efficacy. Conventional drug delivery techniques are giving way to newer, and more effective therapies such as infusion-type medicines, slow-release delivery systems, and implantables.

The global market for ophthalmic drugs is witnessing substantial growth, due primarily to factors such as rising incidence as well as prevalence of eye disorders such as macular degeneration, diabetic retinopathy and presbyopia among the elderly population. Growth is also driven by the evolution of treatment options for age-macular degeneration, as well as the ensuing commercial and therapeutic success of Lucentis, which made the market more lucrative and a potential growth sector.

Conversely, the market is fraught with challenges, including absence of health insurance among the ageing population in developing countries. Meanwhile, low awareness related to ophthalmic disorders, primarily due to little or no awareness in rural areas, pose tremendous challenges for ophthalmic drugs market in developing countries.

The global ophthalmic drug market is likely to face a patent cliff after 2010 as patents of major products within ocular anti-allergic, anti-glaucoma, as well as anti-inflammatory/anti-inflective therapies expire. The market expansion and the development of ophthalmic franchises of major pharmaceutical providers would be hit by the ensuing generic incursion, along with the rising regulatory priorities with regards to the global healthcare reforms.

Though the high efficacy of Allegan/Inspire's Restasis and Roche/Genetech's Lucentis is likely to lead the markets for treatment of dry eye and wet Age-Macular Degeneration, respectively, the global ophthalmology treatment sales are expected to stay more or less flat during the ensuing years.


Key Topics Covered:

1. Introduction, Methodology & Product Definitions

2. Industry Overview

3. Market Dynamics

4. An Overview Of Ophthalmic Drugs

5. Ophthalmic Disorders: A Freeze Frame

6. Fda Approvals And Product Launches

7. Fda Approvals And Product Approvals Launches In The Recent Past - A Perspective Builder

8. Recent Industry Activity

9. Corporate Activity In Recent Past - A Perspective Builder

10. Focus On Select Global Players

11. Global Market Perspective

12. The United States

13. Canada

14. Japan

15. Europe

16. Asia-Pacific

17. Latin America

18. Rest Of World


Companies Mentioned:

  • Aurolab (India)
  • Bohus Biotech AB (Sweden)
  • Cynacon/OCuSOFT (USA)
  • E Fougera & co (USA)
  • Farmak PubJSC (Ukraine)
  • Farmigea SpA (Italy)
  • GSK Consumer Healthcare (Malaysia)
  • GenVec, Inc (USA)
  • Genaera Corporation (USA)
  • Gland Pharma Ltd (India)
  • Hemomont doo (Serbia and Montenegro)
  • Hi-Tech Pharmacal Co, Inc (USA)
  • ISTA Pharmaceuticals (USA)
  • Indkus Drugs And Pharma Pvt, Ltd (India)
  • Insite Vision, Inc (USA)
  • Inspire Pharmaceuticals, Inc (USA)
  • Laboratório Edol Produtos Farmacêuticos, SA (Portugal)
  • Miravant Medical Technology (USA)
  • NPS Pharmaceuticals (USA)
  • Nascent Pharmaceuticals, Inc (USA)
  • Novagali Pharma SA (France):
  • Novartis AG (Switzerland)
  • OSI Pharmaceuticals (USA)
  • Othera Pharmaceuticals (USA)
  • Otsuka Pharmaceutical (Japan)
  • Oxigene, Inc (USA)
  • Pfizer, Inc (USA)
  • QLT, Inc (Canada)
  • Rohto Pharmaceutical Company Ltd (Japan)
  • Sucampo Pharmaceuticals, Inc (USA)
  • Unimed Pharma Sro (Slovakia)
  • Ursapharm Arzneimittel GmbH & Co, KG (Germany)
  • Vitamed Pharmaceutical Industries Ltd (Israel)



For more information visit http://www.researchandmarkets.com/research/wj54rz/ophthalmic#summary



Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net




'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
2. Ophthalmic Instrumentation - Global Strategic Business Report - 2012 Featuring Abbott, Bausch & Lomb, Carl Zeiss and Others
3. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
4. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
5. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
6. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
7. Ohr Pharmaceutical Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board
8. Key Findings: Innovations in Ophthalmic Devices - Anterior Segment
9. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
10. Sony Announces First East and West Coast Installations of 3D Imaging Solution for Ophthalmic Surgery
11. Brazil Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
Breaking Medicine Technology:
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):